Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Y.S.P. Southeast Asia Holding BhdXKLS:7178 -0.50%70 Earnings Yield (Joel Greenblatt) % is 22.78% as of Jun. 2026, which is 56% above its 10-year median of 14.63. GuruFocus rates XKLS:7178 with a GF Score™ of 70/100 and a GF Value™ of RM2.33 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,011 Drug Manufacturers companies, Y.S.P. Southeast Asia Holding Bhd ranks better than 95.45% on this metric.
The historical rank and industry rank for Y.S.P. Southeast Asia Holding Bhd's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
XKLS:7178'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 7.96 Med: 14.63 Max: 24.66
Current: 23.7
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Y.S.P. Southeast Asia Holding Bhd was 24.66%. The lowest was 7.96%. And the median was 14.63%.
XKLS:7178's Earnings Yield (Joel Greenblatt) % is ranked better than 95.45% of 1011
companies
in the Drug Manufacturers industry
Industry Median: 3
vs XKLS:7178: 23.70
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Y.S.P. Southeast Asia Holding Bhd's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 22.83%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Y.S.P. Southeast Asia Holding Bhd Earnings Yield (Joel Greenblatt) % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Y.S.P. Southeast Asia Holding Bhd's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Y.S.P. Southeast Asia Holding Bhd Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Y.S.P. Southeast Asia Holding Bhd's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Y.S.P. Southeast Asia Holding Bhd's Earnings Yield (Joel Greenblatt) % falls into.
Y.S.P. Southeast Asia Holding Bhd Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Y.S.P. Southeast Asia Holding Bhd's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM42.2 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 22.78% mean?
Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) has a Earnings Yield (Joel Greenblatt) % of 22.78% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Y.S.P. Southeast Asia Holding Bhd and its competitors. This is 56% above median its historical median of 14.63. Over the past decade, Y.S.P. Southeast Asia Holding Bhd's Earnings Yield (Joel Greenblatt) % has ranged from 7.96 to 24.66. According to the industry distribution chart, Y.S.P. Southeast Asia Holding Bhd ranks #46 out of 1011 companies in the Drug Manufacturers industry, placing it in the top 4.5%.
Is Y.S.P. Southeast Asia Holding Bhd's Earnings Yield (Joel Greenblatt) % too high?
Y.S.P. Southeast Asia Holding Bhd's current Earnings Yield (Joel Greenblatt) % of 22.78% is 56% above median its 10-year median of 14.63. Over the past 10 years, this metric has ranged from a low of 7.96 to a high of 24.66. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.00. Y.S.P. Southeast Asia Holding Bhd's value of 22.78% is 659.3% above this industry median. Based on the distribution chart, Y.S.P. Southeast Asia Holding Bhd ranks #46 out of 1011 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Y.S.P. Southeast Asia Holding Bhd has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Y.S.P. Southeast Asia Holding Bhd's Earnings Yield (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Y.S.P. Southeast Asia Holding Bhd ranks #46 out of 1011 companies for Earnings Yield (Joel Greenblatt) %. This places Y.S.P. Southeast Asia Holding Bhd in the top 5% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 3.00. Y.S.P. Southeast Asia Holding Bhd's value of 22.78% is 659.3% above this benchmark. Historically, Y.S.P. Southeast Asia Holding Bhd's own Earnings Yield (Joel Greenblatt) % has ranged from 7.96 to 24.66 over the past decade. While the company's 10-year median is 14.63 vs. the industry median of 3.00, Y.S.P. Southeast Asia Holding Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.00, based on 1,011 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Y.S.P. Southeast Asia Holding Bhd's current Earnings Yield (Joel Greenblatt) % of 22.78% is 659.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Y.S.P. Southeast Asia Holding Bhd and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Y.S.P. Southeast Asia Holding Bhd's current Earnings Yield (Joel Greenblatt) % is 22.78%, which is 56% above median its own 10-year median of 14.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Y.S.P. Southeast Asia Holding Bhd stock overvalued right now?
Based on GuruFocus' analysis, Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) is currently considered Modestly Undervalued. The stock's GF Value™ is RM2.33, compared to a current price of RM1.99 — trading 14.6% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 22.78%, which is 56% above median its 10-year median of 14.63 and 659.3% above the Drug Manufacturers industry median of 3.00. Y.S.P. Southeast Asia Holding Bhd's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Y.S.P. Southeast Asia Holding Bhd (XKLS:7178), the current Earnings Yield (Joel Greenblatt) % is 22.78% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) Overvalued in 2026?
Based on GuruFocus' analysis, Y.S.P. Southeast Asia Holding Bhd stock appears to be undervalued.
The current stock price of RM1.99 is trading 14.6% below its estimated GF Value™ of RM2.33.
GuruFocus considers Y.S.P. Southeast Asia Holding Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7178:
Earnings Yield (Joel Greenblatt) %: 22.78% (56% above median its 10-year median of 14.63)
GF Value™: RM2.33 vs. price of RM1.99 (14.6% below fair value)
Industry Position: 659.3% above the Drug Manufacturers median (#46 of 1011)
No single metric tells the full story. See the XKLS:7178 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Y.S.P. Southeast Asia Holding Bhd is an investment company, that engages in the pharmaceutical business, and provision of management services. The company operates through the following segments: Trading, Manufacturing, and Investment Holding. The Trading segment imports, exports, and trading in various kinds of pharmaceutical products, and traditional herbal and veterinary products. The Manufacturing segment manufactures pharmaceutical products. The Investment Holding segment focuses on investment holding activity. The firm's majority of revenue comes from the Manufacturing segment. The majority of revenue is derived from Malaysia.
70GF Score
Get the complete analysis for XKLS:7178
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7178 has been successfully added to your 
